Graves' autoimmune serum inhibits gonadal steroidogenesis: development of a Leydig cell bioassay to identify broad spectrum anti-endocrine autoantibodies

Development of the adult-type Leydig cell population in the rat is affected by neonatal thyroid hormone levels

We have investigated the effects of neonatal-prepubertal changes in thyroid hormone levels on the early phases of adult-type Leydig cell development in the rat testis. Hypothyroidism was induced by adding 6-propyl-2-thiouracil (PTU) to the drinking water, while hyperthyroidism was induced by daily injections with triiodothyronine (T3). The proliferative activity of the Leydig cells in PTU-treated animals was not different from that in age-matched controls through the age of 16 days. Nevertheless, the percentage of Leydig cells (i.e., the proportion of Leydig cells among the total interstitial cell population) was approximately 83% and 67% lower at the ages of 12 and 16 days, respectively. The proliferative activity of the Leydig cells in the T3-treated animals compared to the controls was increased approximately 3-fold at the ages of 12 and 16 days. The percentage of Leydig cells in T3-treated animals was also considerably increased at these two ages (400% and 725%, respectively). Concomitantly, the percentage of peritubular cells was decreased, suggesting that the increase in the percentage of Leydig cells may at least partially be the result of differentiation of peritubularly located precursor cells. Plasma testosterone levels fluctuated considerably at these ages. Hence, injection of T3 during the neonatal-prepubertal period not only affects Sertoli cell proliferation and differentiation but also directly or indirectly affects the onset of the formation of the adult-type Leydig cell population and its function.

The antibodies causing thyroid stimulating hormone-binding inhibition (TSH-BI) are not responsible for the specific inhibition of gonadal steroidogenesis by Graves' sera

Graves' disease is attributed to the presence of autoantibodies with agonist activity which interact with the TSH receptor causing thyroid hyperstimulation and hyperthyroidism. The degree of TSH-binding inhibition (TSH-BI) caused by a Graves' serum in a TSH radioligand receptor assay is considered to be an index of the prevalence of anti-TSH receptor autoantibodies in that serum. We have previously shown that the specific inhibition by Graves' serum of hCG-stimulated steroidogenesis by Leydig cells was at a site distal to receptor binding and second messenger activation. In this report, we have investigated whether the effect of Graves' serum upon Leydig cells is a property of the constitutive antibodies. Immunoglobulin-enriched fractions were obtained from Graves' and normal sera using three increasingly rigorous procedures; ammonium sulphate precipitation, caprylic acid treatment and Protein A or G-affinity purification. The TSH-BI was determined for untreated and extracted sera in two radioreceptor assays developed for use with serum, one using human thyroid membranes and the other using HeLa cells transfected with the human TSH receptor, and the results were compared with effects in the Leydig cell steroidogenesis bioassay. The specific inhibition of hCG-stimulated Leydig cell steroidogenesis by Graves' sera was not retained in the antibody fraction causing TSH-BI. Thus, the inhibitory factor appears not to be an antibody and we are now attempting to purify and identify the responsible factor from Graves' serum.